155 related articles for article (PubMed ID: 29904848)
1. OnabotulinumtoxinA in chronic migraine: long-term efficacy in a prophylactic medication free cohort.
Schiano di Cola F; Pari E; Caratozzolo S; Mancinelli C; Liberini P; Rao R; Padovani A
Neurol Sci; 2018 Jun; 39(Suppl 1):159-160. PubMed ID: 29904848
[No Abstract] [Full Text] [Related]
2. OnabotulinumtoxinA for chronic migraine: a real-life Italian multicenter experience.
Vernieri F; Paolucci M; Altamura C; Pasqualetti P; Mastrangelo V; Pierangeli G; Cevoli S; D'Amico D; Grazzi L
Neurol Sci; 2018 Jun; 39(Suppl 1):171-172. PubMed ID: 29904838
[No Abstract] [Full Text] [Related]
3. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
Silberstein SD; Blumenfeld AM; Cady RK; Turner IM; Lipton RB; Diener HC; Aurora SK; Sirimanne M; DeGryse RE; Turkel CC; Dodick DW
J Neurol Sci; 2013 Aug; 331(1-2):48-56. PubMed ID: 23790235
[TBL] [Abstract][Full Text] [Related]
4. OnabotulinumtoxinA for chronic migraine.
Blumenfeld A; Evans RW
Headache; 2012 Jan; 52(1):142-8. PubMed ID: 22268776
[No Abstract] [Full Text] [Related]
5. OnabotulinumtoxinA for the treatment of chronic migraine not quite there. .
Torgovnick J
Cephalalgia; 2011 Feb; 31(3):377; author reply 378-9. PubMed ID: 21098110
[No Abstract] [Full Text] [Related]
6. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.
Diener HC; Dodick DW; Aurora SK; Turkel CC; DeGryse RE; Lipton RB; Silberstein SD; Brin MF;
Cephalalgia; 2010 Jul; 30(7):804-14. PubMed ID: 20647171
[TBL] [Abstract][Full Text] [Related]
7. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
Aurora SK; Dodick DW; Turkel CC; DeGryse RE; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Cephalalgia; 2010 Jul; 30(7):793-803. PubMed ID: 20647170
[TBL] [Abstract][Full Text] [Related]
8. OnabotulinumtoxinA for treatment of chronic migraine: a response.
Dodick DW; Turkel CC; Degryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF
Headache; 2011 Jun; 51(6):1005-8. PubMed ID: 21592099
[No Abstract] [Full Text] [Related]
9. CALCA and TRPV1 genes polymorphisms are related to a good outcome in female chronic migraine patients treated with OnabotulinumtoxinA.
Moreno-Mayordomo R; Ruiz M; Pascual J; Gallego de la Sacristana M; Vidriales I; Sobrado M; Cernuda-Morollon E; Gago-Veiga AB; Garcia-Azorin D; Telleria JJ; Guerrero AL
J Headache Pain; 2019 Apr; 20(1):39. PubMed ID: 31014225
[TBL] [Abstract][Full Text] [Related]
10. OnabotulinumtoxinA (BOTOX®): a guide to its use in preventing headaches in adults with chronic migraine.
Lyseng-Williamson KA; Frampton JE
CNS Drugs; 2012 Aug; 26(8):717-23. PubMed ID: 22784019
[TBL] [Abstract][Full Text] [Related]
11. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
Lipton RB; Varon SF; Grosberg B; McAllister PJ; Freitag F; Aurora SK; Dodick DW; Silberstein SD; Diener HC; DeGryse RE; Nolan ME; Turkel CC
Neurology; 2011 Oct; 77(15):1465-72. PubMed ID: 21956721
[TBL] [Abstract][Full Text] [Related]
12. Wearing Off Response to OnabotulinumtoxinA in Chronic Migraine: Analysis in a Series of 193 Patients.
Quintas S; García-Azorín D; Heredia P; Talavera B; Gago-Veiga AB; Guerrero ÁL
Pain Med; 2019 Sep; 20(9):1815-1821. PubMed ID: 30657951
[TBL] [Abstract][Full Text] [Related]
13. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
[TBL] [Abstract][Full Text] [Related]
14. Botox for chronic migraine.
Drug Ther Bull; 2011 Feb; 49(2):22-4; quiz iii-iv. PubMed ID: 21304165
[TBL] [Abstract][Full Text] [Related]
15. Refractory chronic migraine: is drug withdrawal necessary before starting a therapy with onabotulinum toxin type A?
Butera C; Colombo B; Bianchi F; Cursi M; Messina R; Amadio S; Guerriero R; Comi G; Del Carro U
Neurol Sci; 2016 Oct; 37(10):1701-6. PubMed ID: 27395386
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: Retrospective analysis of a US-based insurance claims database.
Hepp Z; Rosen NL; Gillard PG; Varon SF; Mathew N; Dodick DW
Cephalalgia; 2016 Aug; 36(9):862-74. PubMed ID: 26692400
[TBL] [Abstract][Full Text] [Related]
17. OnabotulinumtoxinA for treatment of chronic migraine: the unblinding problem.
Solomon S
Headache; 2013 May; 53(5):824-6. PubMed ID: 23465058
[No Abstract] [Full Text] [Related]
18. Prophylactic botulinum type A toxin complex (Dysport®) for migraine without aura.
Chankrachang S; Arayawichanont A; Poungvarin N; Nidhinandana S; Boonkongchuen P; Towanabut S; Sithinamsuwan P; Kongsaengdao S
Headache; 2011 Jan; 51(1):52-63. PubMed ID: 21083558
[TBL] [Abstract][Full Text] [Related]
19. Botulinum neurotoxin A for chronic migraine headaches: does it work and how?
Cairns BE; Gazerani P
Pain Manag; 2014; 4(6):377-80. PubMed ID: 25494688
[No Abstract] [Full Text] [Related]
20. Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety.
Blumenfeld AM; Tepper SJ; Robbins LD; Manack Adams A; Buse DC; Orejudos A; D Silberstein S
J Neurol Neurosurg Psychiatry; 2019 Mar; 90(3):353-360. PubMed ID: 30630956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
